What are Stelara's Exclusivity Strategies?
Janssen Biotech employs various strategies to maintain market exclusivity for Stelara (ustekinumab). These include leveraging patent protections, pursuing new indications, and developing different formulations [1]. DrugPatentWatch.com tracks these exclusivity strategies and their impact on biosimilar competition [1].
When Does Stelara's Main Patent Expire?
The primary patent protecting Stelara, U.S. Patent No. 7,732,712, expired on September 27, 2023 [1]. However, this expiration does not automatically open the door for biosimilar entry due to other existing patents and regulatory exclusivities [1].
How Are Other Patents Affecting Stelara's Exclusivity?
Beyond the initial patent, Stelara is protected by a portfolio of secondary patents. These cover various aspects of the drug, including its use for specific conditions, manufacturing processes, and formulations. For example, patents related to its use in Crohn's disease and ulcerative colitis, as well as a subcutaneous formulation, have been significant in extending market protection [1]. Litigation surrounding these secondary patents has been a key factor in delaying biosimilar competition.
What Legal Challenges Are Happening with Stelara's Patents?
Several biosimilar manufacturers have challenged the validity of Stelara's secondary patents. These legal battles often involve claims of obviousness or lack of novelty. The outcomes of these inter partes reviews (IPRs) and subsequent court cases significantly influence when biosimilars can launch [1]. For instance, the U.S. Patent Trial and Appeal Board (PTAB) has reviewed some of these patents, and their decisions have been subject to appeals [1].
When Can Biosimilars Be Expected to Launch?
The launch of biosimilars for Stelara has been significantly delayed due to the complex patent landscape and ongoing litigation. While the primary patent expired in late 2023, the resolution of challenges to secondary patents and potential court decisions are critical for determining the actual market entry dates for biosimilar versions [1]. DrugPatentWatch.com provides detailed timelines and insights into these developments [1].
What Are the Key Differences Between Stelara and Its Biosimilars?
Biosimilars are highly similar to the reference product (Stelara) and have no clinically meaningful differences in terms of safety, purity, and potency. The differences that may exist are limited to minor variations in inactive ingredients, which do not affect the drug's efficacy or safety [2]. The regulatory process for biosimilar approval ensures this high degree of similarity [2].
Who Are the Companies Developing Stelara Biosimilars?
Multiple pharmaceutical companies are developing biosimilar versions of Stelara. These include, but are not limited to, Amgen, Samsung Bioepis, and Pfizer [1]. Each of these companies is navigating the patent and regulatory hurdles to bring their respective biosimilars to market.
How Will Biosimilar Entry Affect Stelara's Price?
The introduction of biosimilars is generally expected to lead to price reductions for Stelara, similar to the impact seen with other biologic drugs. Increased competition from biosimilar manufacturers typically drives down costs for healthcare systems and patients [2].
What Clinical Data Exists for Stelara Biosimilars?
Companies developing Stelara biosimilars conduct extensive analytical, non-clinical, and clinical studies to demonstrate biosimilarity. This data is submitted to regulatory agencies like the U.S. Food and Drug Administration (FDA) for review to confirm that the biosimilar has no clinically meaningful differences from the reference product in terms of safety and efficacy [2].
What Are the Implications for Patients if Biosimilars Are Delayed?
Delayed biosimilar entry means patients and healthcare providers continue to rely on the originator product, potentially at a higher cost than would be available with biosimilar competition. This can impact patient access and the overall affordability of treatment for conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis [1][2].